Please use this identifier to cite or link to this item:
Title: Breast and Prostate Cancer Risks for Male BRCA1 and BRCA2 Pathogenic Variant Carriers Using Polygenic Risk Scores
Author: Barnes, Daniel R.
Angel Pujana, Miquel
Teulé Vega, Àlex
Balmaña, Judith
GEMO Study Collaborators
EMBRACE Collaborators
KConFab Investigators
HEBON Investigators
Consortium Of Investigators Of Modifiers Of Brca1 And Brca2, The
Brunet, Joan
Darder, Esther
Valle Domínguez, Jesús del
Diez, Orland
Feliubadaló i Elorza, Maria Lídia
Izquierdo, Angel
Lazaro, Conxi
López Fernández, Adrià
Keywords: Càncer de mama
Càncer de pròstata
Breast cancer
Prostate cancer
Issue Date: 28-Jul-2021
Publisher: Oxford University Press (OUP)
Abstract: Background: Recent population-based female breast cancer and prostate cancer polygenic risk scores (PRS) have been developed. We assessed the associations of these PRS with breast and prostate cancer risks for male BRCA1 and BRCA2 pathogenic variant carriers. Methods: 483 BRCA1 and 1318 BRCA2 European ancestry male carriers were available from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA). A 147-single nucleotide polymorphism (SNP) prostate cancer PRS (PRSPC) and a 313-SNP breast cancer PRS were evaluated. There were 3 versions of the breast cancer PRS, optimized to predict overall (PRSBC), estrogen receptor (ER)-negative (PRSER-), or ER-positive (PRSER+) breast cancer risk. Results: PRSER+ yielded the strongest association with breast cancer risk. The odds ratios (ORs) per PRSER+ standard deviation estimates were 1.40 (95% confidence interval [CI] =1.07 to 1.83) for BRCA1 and 1.33 (95% CI = 1.16 to 1.52) for BRCA2 carriers. PRSPC was associated with prostate cancer risk for BRCA1 (OR = 1.73, 95% CI = 1.28 to 2.33) and BRCA2 (OR = 1.60, 95% CI = 1.34 to 1.91) carriers. The estimated breast cancer odds ratios were larger after adjusting for female relative breast cancer family history. By age 85 years, for BRCA2 carriers, the breast cancer risk varied from 7.7% to 18.4% and prostate cancer risk from 34.1% to 87.6% between the 5th and 95th percentiles of the PRS distributions. Conclusions: Population-based prostate and female breast cancer PRS are associated with a wide range of absolute breast and prostate cancer risks for male BRCA1 and BRCA2 carriers. These findings warrant further investigation aimed at providing personalized cancer risks for male carriers and informing clinical management.
Note: Reproducció del document publicat a:
It is part of: JNCI: Journal of the National Cancer Institute, 2021, vol 114, num 1, p. 109-122
Related resource:
ISSN: 1460-2105
Appears in Collections:Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))

Files in This Item:
File Description SizeFormat 
10.1093-jnci-djab147-39355070.pdf6.39 MBAdobe PDFView/Open

This item is licensed under a Creative Commons License Creative Commons